logo-loader
viewNemaura Medical Inc

Nemaura to launch digital healthcare subscription service proBEAT in US

proBEAT is expected to be available without a prescription for adults who are pre-diabetic or have Type 2 diabetics

Nemaura Medical Inc - Nemaura Medical Inc of the UK planning to launch a digital healthcare subscription service in the US under the brand name proBEAT
Nemaura intends to market proBEAT as a general wellness product per FDA guidelines

Nemaura Medical Inc (NASDAQ:NMRD), a UK-based company focused on diabetes, announced Monday that it is planning to launch a digital healthcare subscription service in the US under the brand name proBEAT.

The company said that proBEAT is expected to be available without the need for a prescription and appeal to a broad range of adults encompassing pre-diabetic and Type 2 diabetics - 88 million and 26 million people, respectively - as well as those seeking to lose weight and have a healthier lifestyle.

Nemaura said proBEAT can help users improve their knowledge of how a range of lifestyle, dietary and health and wellbeing factors impact their sugar levels by acting like a black box flight recorder. 

READ: Nemaura preparing for launch of sugarBEAT glucose monitor in the US

“Big data about the multitude of factors that affect glucose levels will be gathered from all users and employed in developing and subsequently ‘fine-tuning’ predictive algorithms and artificial intelligence-based feedback and prompts,” the company said in a statement.

“These will then be able to both educate and provide motivational tools to the user to encourage them to lead a healthier lifestyle.”

Nemaura said it is now prioritizing launch plans for its proBEAT digital health platform in the US and is considering various options to expedite the launch, including partnering with multi-national companies.

Nemaura said it intends to market proBEAT as a general wellness product per the US Food and Drug Administration’s (FDA) rules.

General wellness products outlined in FDA guidance are those which have either: 

  • An intended use that relates to maintaining or encouraging a general state of health or a healthy activity
  • Or intended use that relates the role of a healthy lifestyle with helping to reduce the risk or impact of certain chronic diseases or disease conditions and where it is well understood and accepted that healthy lifestyle choices may play an important role in health outcomes for the disease or condition

The company also plans to launch its sugarBEAT continuous glucose monitor in the US. SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: Nemaura Medical Inc

Price: 7.67 USD

NASDAQ:NMRD
Market: NASDAQ
Market Cap: $159.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Canntab Therapeutics gets first commercial sale with Medipharm

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein and Special Advisor Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has signed their first contract for their slow release tablets with MediPharm.  Goldstein discusses how the...

7 hours, 57 minutes ago

2 min read